# Zhejiang Dejin Biopharmaceutical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zhejiang-dejin-biopharmaceutical-technology-co

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Latest round: Series A (Jan 20, 2026)
- Investors on record: 1

## About

Based in Hangzhou, China and founded in 2023, Zhejiang Dejin Biopharmaceutical Technology Co., Ltd. provides synthetic biopharmaceutical solutions for the healthcare industry. The company was established to apply gene engineering to the production of botulinum toxin, aiming to lower costs and improve safety compared to traditional methods. In January 2026, it closed a series A funding round led by HighLight Capital.

The company works with medical institutions in the medical aesthetics industry to provide advanced toxin products. The company develops recombinant botulinum toxin injections (such as DJ-01) using a proprietary gene engineering strain design platform. 

The company’s revenue is generated by the direct sale of its recombinant botox products to hospitals and aesthetic clinics. 

The company plans to use the series A funding to advance the clinical research of its core recombinant botulinum toxin product DJ-01, build an industrialization base, and expand its international layout.

## Funding rounds

- Series A, Jan 20, 2026 — HighLight Capital

## Investors

- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series A